Molecular Profiling of Malignant Pleural Effusion in Metastatic Non–Small-Cell Lung Carcinoma. The Effect of Preanalytical Factors
- 1 July 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 14 (7) , 1169-1176
Abstract
Rationale: Non–small-cell lung cancer (NSCLC)–associated malignant pleural effusions (MPEs) are sometimes the only available specimens for molecular analysis. Objectives: This study evaluates diagnostic yield of NSCLC-associated MPE, its adequacy for molecular profiling and the potential influence of MPE volume/cellularity on the analytic sensitivity of our assays. Methods: Molecular results of 50 NSCLC-associated MPE cases during a 5-year period were evaluated. Molecular profiling was performed on cell blocks and consisted of fluorescent in situ hybridization (FISH) for ALK gene rearrangements and the following sequencing platforms: Sanger sequencing (for EGFR) and high-throughput pyrosequencing (for KRAS and BRAF) during the first 4 years of the study period, and targeted next-generation sequencing performed thereafter. Results: A total of 50 NSCLC-associated MPE cases were identified where molecular testing was requested. Of these, 17 cases were excluded: 14 cases (28%) due to inadequate tumor cellularity and 3 cases due to unavailability of the slides to review. A total of 27 out of 50 MPE cases (54%) underwent at least EGFR and KRAS sequencing and FISH for ALK rearrangement. Of the 27 cases with molecular testing results available, a genetic abnormality was detected in 16 cases (59%). The most common genetic aberrations identified involved EGFR (9) and KRAS (7). Six cases had ALK FISH only, of which one showed rearrangement. MPE volume was not associated with overall cellularity or tumor cellularity (P = 0.360). Conclusions: Molecular profiling of MPE is a viable alternative to testing solid tissue in NSCLC. This study shows successful detection of genetic aberrations in 59% of samples with minimal risk of false negative.Keywords
This publication has 27 references indexed in Scilit:
- A single EBUS-TBNA procedure can support a large panel of immunohistochemical stains, specific diagnostic subtyping, and multiple gene analyses in the majority of non–small cell lung cancer casesHuman Pathology, 2016
- EGFR mutations in malignant pleural effusions from lung cancerCurrent Pulmonology Reports, 2013
- Molecular Genetics and Personalized Medicine2012
- EGFR and KRAS mutations in metastatic lung adenocarcinomasHuman Pathology, 2011
- Sequencing technologies and genome sequencingJournal of Applied Genetics, 2011
- Δ-PCR, A Simple Method to Detect Translocations and Insertion/Deletion MutationsThe Journal of Molecular Diagnostics, 2011
- Sequencing technologies — the next generationNature Reviews Genetics, 2009
- EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinibLung Cancer, 2007
- Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancerInternational Journal of Cancer, 2006
- EGFR mutations in malignant pleural effusion of non-small cell lung cancer: A case reportLung Cancer, 2005